2024-09-062024-09-062012-07-011309-0720https://doi.org/10.4328/JCAM.705https://hdl.handle.net/11452/44359Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non -small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages a70 years) who received PC for stage III (n=111 or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-62). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.795). There was no treatment related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC.eninfo:eu-repo/semantics/closedAccessNon-small cellLungElderlyChemotherapyScience & technologyLife sciences & biomedicineMedicine, general & internalGeneral & internal medicineArticle0002155474000122932953310.4328/JCAM.705